Top Markets
Coin of the day
Innate Pharma S.A. Innate Pharma S.A.

Innate Pharma S.A.

IPH
Helyezés a részvények között #18401
Innate Pharma S.A. is a biotechnology firm dedicated to the discovery,... Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company's pipeline includes several key drug candidates: Lacutamab (IPH4102), an anti-KIR3DL2 antibody, is currently in Phase II clinical trials for treating cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab, an immune checkpoint inhibitor, is undergoing Phase III evaluation for advanced solid tumors, encompassing colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401), a monoclonal antibody designed to block C5a binding to C5aR1, is advancing through Phase II studies for conditions such as COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases. IPH5201, a blocking antibody, is in Phase I clinical trials, aiming to modulate the CD39 immunosuppressive pathway. IPH5301, an anti-CD73 antibody, targets the immunosuppressive adenosine pathway to foster anti-tumor immunity. IPH6101, an NKp46-based NK cell engager, is being developed for the creation and assessment of up to two bispecific NK cell engagers. Beyond clinical stages, their preclinical programs feature IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), along with the IPH62 and IPH64 programs. Innate Pharma S.A. maintains strategic alliances and licensing deals with prominent pharmaceutical entities including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, in addition to a co-development and licensing agreement with MedImmune Limited. The company was founded in 1999 and has its headquarters located in Marseille, France.
Részvényárfolyam
$2.13
Utolsó szinkronizálás: 2026-09-02
Piaci kapitalizáció
$200.27M
Változás (1 nap)
0.90%
Változás (1 év)
-1.67%
Ország
FR
Kereskedés Innate Pharma S.A. (IPH)

Kategória

Részvényfelosztások története: Innate Pharma S.A. (IPH)
Innate Pharma S.A. részvény (szimbólum: IPH) összesen 0 részvényfelosztáson ment keresztül.
A legutóbbi felosztás dátuma: Sep 03, 2026.
Egy IPH részvény, amelyet a(z) Sep 03, 2026 előtt vásároltak, ma 0 IPH részvénynek felel meg.
Részvényfelosztások listája
Év Felosztás Szorzó Halmozott szorzó
Nincs elég adat a megadott dátumokhoz.
Részvényfelosztások hasonló cégeknél vagy versenytársaknál
Vállalat Részvényfelosztások száma Halmozott szorzó Ország
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH